ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0697

Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis

Adam Mayer1, Weiming Hu2, Kyle Bittinger2, Rui Liang3, Naomi Amudala3, Shubhasree Banerjee3, Peter Merkel3 and Rennie Rhee3, 1University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2023

Keywords: giant cell arteritis, microbiome, Takayasu.s arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The gut microbiome has a critical role in immune homeostasis and there is growing interest in understanding the relationship between the microbiome and autoimmunity. There are epidemiologic and genetic associations between large-vessel vasculitis (LVV) and inflammatory bowel disease, an autoimmune disease where intestinal dysbiosis is common. This study evaluated the relationship between composition and function of gut microbiota and disease activity in patients with LVV.

Methods: In this longitudinal, prospective cohort study, stool samples and clinical data were collected from patients with giant cell arteritis (GCA) and Takayasu arteritis (TAK) every 6 months at a single center. Diagnosis and disease activity of LVV were determined by the investigator and informed by the 1990 ACR classification criteria and BVAS, respectively. Healthy control patients without autoimmune disease were also recruited and supplemented by existing healthy control stool microbiome data from a separate convenience cohort. The fecal microbiome was profiled using shotgun metagenomic sequencing. Comparisons to healthy controls were conducted using samples from the first visit at which: 1) LVV was inactive, and 2) LVV was active. The relative abundance of microbial taxa in the stool was estimated using Kraken2, and the relative abundance of microbial gene orthologs was determined by alignment to the Kyoto Encyclopedia of Genes and Genomes (KEGG). Community-level differences in taxonomic (beta diversity) and gene function composition in the microbiome were assessed using Bray-Curtis distances between samples in principle coordinate analysis (PCoA) plots. The relative abundance of the 10 most common functional pathways, determined by the abundance of constituent genes, was compared using heatmaps and linear models. P-values were adjusted to control for a false discovery rate of 5% when multiple comparisons were made.

Results: 27 patients with LVV, which included 16 with GCA and 11 with TAK, and 23 healthy controls were included in the study with a total of 76 stool samples obtained. GCA patients were 75% female with mean age 70.4 years (SD 6.5) while TAK patients were all female with mean age 37.2 years (SD 13.8). Eight patients with LVV experienced a flare with the most common symptoms in GCA being constitutional symptoms (75%) and headache (50%) and in TAK chest pain/dyspnea (50%) and lower limb claudication (25%). Composition of fecal microbiota, measured by beta diversity, was significantly different in active LVV samples but not inactive LVV when compared to controls (Figure 1). In our analysis of microbial gene ortholog abundance, functional genes of bacteria were significantly different in both active and inactive LVV patients compared to controls (Figure 2). Several microbial gene pathways were identified to distinguish patients with active LVV from controls, but few emerged in our comparison of inactive LVV and controls (Figure 3).

Conclusion: Patients with LVV, particularly those with active disease, have altered composition, functional genes and pathways of gut microbiota compared to healthy controls. The possibility of shared mechanisms driving the altered microbiome in GCA and TAK warrants further investigation.

Supporting image 1

Figure 1. Bacterial composition in large-vessel vasculitis (inactive and active) vs controls. Principal coordinate analysis (PCoA) plots compare beta diversity between controls vs inactive vasculitis (left panel) and active vasculitis (right panel) using Bray-Curtis distances. Beta diversity did not significantly differ when comparing inactive LVV to controls (p=0.21) but did between active vasculitis and controls (p<0.01).

Supporting image 2

Figure 2. Bacterial functional analysis in large-vessel vasculitis (inactive and active) vs controls. PCoA plots compare microbial metagenomic functional composition in inactive vasculitis (left panel) and active vasculitis (right panel) compared to controls using Bray-Curtis distances. These distributions significantly differed between controls and vasculitis subgroups both during inactive disease (p<0.01) and active disease (p<0.01).

Supporting image 3

Figure 3. Functional pathways of gut microbiota in large-vessel vasculitis vs controls. Heatmaps representing relative abundance of functional pathways between control patients, patients with giant cell arteritis, and patients with Takayasu arteritis. While few pathways significantly differed between groups during inactive vasculitis (top), more significant differences were observed from samples during active vasculitis (bottom).


Disclosures: A. Mayer: None; W. Hu: None; K. Bittinger: None; R. Liang: None; N. Amudala: None; S. Banerjee: None; P. Merkel: AbbVie/Abbott, 5, Amgen, 2, 5, ArGenx, 2, AstraZeneca, 2, 5, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, Cabaletta, 2, CSL Behring, 2, Eicos, 5, Electra, 5, Genentech, 5, GlaxoSmithKlein(GSK), 2, 5, HiBio, 2, InflaRx, 2, 5, Janssen, 2, Jubilant, 2, Kyverna, 2, 11, MiroBio, 2, Neutrolis, 5, Novartis, 2, NS Pharma, 2, Q32, 2, Regeneron, 2, Sanofi, 2, Sparrow, 2, Takeda, 2, 5, UpToDate, 9, Visterra, 2; R. Rhee: None.

To cite this abstract in AMA style:

Mayer A, Hu W, Bittinger K, Liang R, Amudala N, Banerjee S, Merkel P, Rhee R. Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/alterations-in-composition-and-function-of-gut-microbiota-in-patients-with-large-vessel-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/alterations-in-composition-and-function-of-gut-microbiota-in-patients-with-large-vessel-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology